JP2008501034A - ポサコナゾールを含む注射用薬学的懸濁液 - Google Patents

ポサコナゾールを含む注射用薬学的懸濁液 Download PDF

Info

Publication number
JP2008501034A
JP2008501034A JP2007515456A JP2007515456A JP2008501034A JP 2008501034 A JP2008501034 A JP 2008501034A JP 2007515456 A JP2007515456 A JP 2007515456A JP 2007515456 A JP2007515456 A JP 2007515456A JP 2008501034 A JP2008501034 A JP 2008501034A
Authority
JP
Japan
Prior art keywords
formulation
posaconazole
hour
average
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007515456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501034A5 (enExample
Inventor
レオノーレ ウィッチー−ラクシュマナン，
シドニー ウグウ，
バルダ サンドウェイス，
キャサリン ハルダロ，
ロベルタ エス． ヘア，
ゴパル クリシュナ，
ザイチー ワン，
マルコ タグレッティ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008501034(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2008501034A publication Critical patent/JP2008501034A/ja
Publication of JP2008501034A5 publication Critical patent/JP2008501034A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007515456A 2004-05-28 2005-05-27 ポサコナゾールを含む注射用薬学的懸濁液 Withdrawn JP2008501034A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28
PCT/US2005/018945 WO2005117831A1 (en) 2004-05-28 2005-05-27 Injectable pharmaceutical suspension comprising posaconazole

Publications (2)

Publication Number Publication Date
JP2008501034A true JP2008501034A (ja) 2008-01-17
JP2008501034A5 JP2008501034A5 (enExample) 2008-07-03

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515456A Withdrawn JP2008501034A (ja) 2004-05-28 2005-05-27 ポサコナゾールを含む注射用薬学的懸濁液

Country Status (15)

Country Link
EP (1) EP1761247A1 (enExample)
JP (1) JP2008501034A (enExample)
KR (1) KR20070027564A (enExample)
CN (1) CN1988887A (enExample)
AR (1) AR049063A1 (enExample)
AU (1) AU2005249502A1 (enExample)
CA (1) CA2567803A1 (enExample)
IL (1) IL179627A0 (enExample)
MX (1) MXPA06013886A (enExample)
NO (1) NO20066005L (enExample)
PE (1) PE20060291A1 (enExample)
RU (1) RU2006146555A (enExample)
TW (1) TWI290051B (enExample)
WO (1) WO2005117831A1 (enExample)
ZA (1) ZA200609890B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535422A (ja) * 2010-06-29 2013-09-12 メルク・シャープ・エンド・ドーム・コーポレイション 置換β−シクロデキストリンにより安定化されたポサコナゾール静脈注射用溶液製剤

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
RS56044B1 (sr) * 2006-05-12 2017-09-29 Christian Noe Primena kombinovanih preparata koji sadrže antimikotike
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
EP2451805A1 (en) 2009-07-09 2012-05-16 Sandoz AG A crystalline form of posaconazole
WO2011144656A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Preparation of posaconazole intermediates
WO2011144655A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Process for the preparation of chiral hydrazides
CA2798010C (en) 2010-05-19 2018-09-25 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
RU2585760C2 (ru) 2010-05-19 2016-06-10 Сандоз Аг Способ получения хиральных триазолонов
CN108329303A (zh) 2011-06-16 2018-07-27 桑多斯股份公司 制备手性化合物的方法
CN103284959B (zh) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 泊沙康唑冻干粉针剂及制备方法
CN102755628B (zh) * 2012-07-16 2013-10-23 中国科学院微生物研究所 一种抗真菌的药物组合物
CN102805731B (zh) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 泊沙康唑干混悬剂及其制备方法
CN105030668B (zh) * 2015-06-26 2018-03-27 济川药业集团有限公司 泊沙康唑口服混悬剂及其制备方法
CN106333925B (zh) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 一种泊沙康唑液体混悬剂及其制备方法
CN105997872B (zh) * 2016-07-08 2019-02-19 河南省立眼科医院 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
CA3063115A1 (en) * 2017-04-12 2018-10-18 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
CN110507609B (zh) * 2018-05-21 2021-09-17 上海医药工业研究院 泊沙康唑口服混悬剂的制备方法
CN111514146A (zh) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 含有泊沙康唑的药物组合物
CN113933131B (zh) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 一种阴道微生物荧光染色液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
EP2090165A3 (en) * 2001-04-03 2012-03-28 Schering Corporation Antifungal composition with enhanced bioavailability

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535422A (ja) * 2010-06-29 2013-09-12 メルク・シャープ・エンド・ドーム・コーポレイション 置換β−シクロデキストリンにより安定化されたポサコナゾール静脈注射用溶液製剤

Also Published As

Publication number Publication date
NO20066005L (no) 2007-02-27
EP1761247A1 (en) 2007-03-14
TWI290051B (en) 2007-11-21
RU2006146555A (ru) 2008-07-20
WO2005117831A1 (en) 2005-12-15
AR049063A1 (es) 2006-06-21
ZA200609890B (en) 2008-09-25
KR20070027564A (ko) 2007-03-09
PE20060291A1 (es) 2006-04-14
CN1988887A (zh) 2007-06-27
TW200609001A (en) 2006-03-16
AU2005249502A1 (en) 2005-12-15
CA2567803A1 (en) 2005-12-15
IL179627A0 (en) 2007-05-15
MXPA06013886A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
JP2008501034A (ja) ポサコナゾールを含む注射用薬学的懸濁液
US20090226527A1 (en) Particulate-stabilized injectable pharmacutical compositions of posaconazole
US7989432B2 (en) Micelles
TWI556838B (zh) 治療關節炎之方法
RU2618456C2 (ru) Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
RU2660585C2 (ru) Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
AU2001238507A1 (en) Micelles
US20060009469A1 (en) Particulate-stabilized injectable pharmacutical compositions of posaconazole
TW202024058A (zh) 用於治療真菌感染之化合物及方法
EP3593788A1 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
US20250082574A1 (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
US11285148B1 (en) Ketoconazole ophthalmic preparations containing trans-ethosomal drug nanoparticles
US20230301914A1 (en) Pharmaceutical compositions in lyophilized form
CN107811969B (zh) 一种高稳定性的非囊泡型纳米颗粒及其在治疗真菌感染中的应用
JP2025501992A (ja) 脂質ナノ粒子と抗真菌性ポリエンとを含む組成物
EA048772B1 (ru) Фармацевтические композиции в лиофилизированной форме
HK40040387A (en) Injectable compositions of triterpenoid antifungals encapsulated in liposomes
HK1201723B (en) Pharmaceutical compositions to reduce complications of ocular steroid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080514

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080722